JP2017529851A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529851A5 JP2017529851A5 JP2017516350A JP2017516350A JP2017529851A5 JP 2017529851 A5 JP2017529851 A5 JP 2017529851A5 JP 2017516350 A JP2017516350 A JP 2017516350A JP 2017516350 A JP2017516350 A JP 2017516350A JP 2017529851 A5 JP2017529851 A5 JP 2017529851A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cells
- car
- cell
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462055979P | 2014-09-26 | 2014-09-26 | |
| US62/055,979 | 2014-09-26 | ||
| PCT/US2015/052227 WO2016049459A1 (en) | 2014-09-26 | 2015-09-25 | Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017529851A JP2017529851A (ja) | 2017-10-12 |
| JP2017529851A5 true JP2017529851A5 (enExample) | 2018-11-08 |
Family
ID=55582053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516350A Pending JP2017529851A (ja) | 2014-09-26 | 2015-09-25 | 養子免疫療法のためのグリピカン−３特異的キメラ抗原レセプター |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20170281683A1 (enExample) |
| EP (2) | EP3198010B1 (enExample) |
| JP (1) | JP2017529851A (enExample) |
| DE (1) | DE20196219T1 (enExample) |
| ES (2) | ES2851123T1 (enExample) |
| WO (1) | WO2016049459A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4086285A1 (en) | 2016-02-25 | 2022-11-09 | Cell Medica Switzerland AG | Binding members to pd-l1 |
| CN109414512A (zh) | 2016-04-22 | 2019-03-01 | 科济生物医药（上海）有限公司 | 用于细胞免疫疗法的组合物和方法 |
| CN110035768A (zh) | 2016-07-26 | 2019-07-19 | 泰莎治疗私人有限公司 | 嵌合抗原受体 |
| CN110352068A (zh) | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| JP2018093823A (ja) * | 2016-12-15 | 2018-06-21 | Ｈｅａｒｔｓｅｅｄ株式会社 | 未分化幹細胞除去剤及び未分化幹細胞除去方法 |
| TWI831365B (zh) | 2017-01-10 | 2024-02-01 | 國立大學法人山口大學 | 抗ｇｐｃ３抗體 |
| EP3615574B1 (en) | 2017-04-26 | 2026-06-24 | Eureka Therapeutics, Inc. | Constructs specifically recognizing glypican 3 and uses thereof |
| EP3441461A1 (en) * | 2017-08-11 | 2019-02-13 | Baylor College of Medicine | Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy |
| US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| CN112368298A (zh) | 2018-06-22 | 2021-02-12 | 凯德药业股份有限公司 | 嵌合跨膜蛋白及其用途 |
| US20210261646A1 (en) * | 2018-07-03 | 2021-08-26 | Sotio, LLC | Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof |
| WO2020017479A1 (ja) * | 2018-07-17 | 2020-01-23 | ノイルイミューン・バイオテック株式会社 | 抗ｇｐｃ３一本鎖抗体を含むｃａｒ |
| WO2020037066A1 (en) | 2018-08-14 | 2020-02-20 | Unum Therapeutics Inc. | Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof |
| US12698340B2 (en) | 2018-10-01 | 2026-08-04 | Adicet Therapeutics, Inc. | Compositions and methods regarding engineered and non-engineered γδ T-cells for treatment of solid tumors |
| US20210386788A1 (en) | 2018-10-24 | 2021-12-16 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| CA3118889A1 (en) * | 2018-11-07 | 2020-05-14 | Sotio, LLC | Anti-gpc3 chimeric antigen receptors (cars) in combination with trans co-stimulatory molecules and therapeutic uses thereof |
| WO2020123716A1 (en) | 2018-12-11 | 2020-06-18 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
| CN113286875B (zh) * | 2018-12-19 | 2024-08-09 | Inserm(法国国家健康医学研究院) | 表达嵌合抗原受体的黏膜相关不变t(mait)细胞 |
| BR112021017744A2 (pt) | 2019-03-08 | 2021-11-16 | Obsidian Therapeutics Inc | Composições e métodos de cd40l para regulação ajustável |
| WO2020200303A1 (zh) * | 2019-04-04 | 2020-10-08 | 上海医药集团股份有限公司 | 一种包含肿瘤抗原识别受体的免疫细胞及其应用 |
| CA3140668A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| WO2020252404A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| CN114391021B (zh) | 2019-06-21 | 2026-01-16 | 凯德药业股份有限公司 | TGF-β受体和使用方法 |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| JP7747645B2 (ja) * | 2020-02-27 | 2025-10-01 | レジェンド バイオテック アイルランド リミテッド | グリピカン－３（ｇｐｃ３）を標的化する抗体及びキメラ抗原受容体並びにその使用方法 |
| KR102957804B1 (ko) * | 2020-03-18 | 2026-04-28 | 주식회사 유틸렉스 | Gpc3 car-t 세포 조성물 및 이의 제조 및 사용 방법 |
| WO2021186395A1 (en) * | 2020-03-18 | 2021-09-23 | Eutilex Co., Ltd. | Gpc3 car- t cells secreting il-18 and methods of making and using the same |
| CA3188656A1 (en) | 2020-07-17 | 2022-01-20 | Simurx, Inc. | Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods |
| CN112225822B (zh) * | 2020-12-14 | 2021-03-23 | 北京基因启明生物科技有限公司 | 高扩增、存续能力和杀瘤作用的CAR-iNKT及应用 |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| WO2022148332A1 (zh) * | 2021-01-07 | 2022-07-14 | 上海交通大学 | 改造的免疫效应细胞及其用途 |
| US20260116991A1 (en) * | 2021-02-03 | 2026-04-30 | Hainan Simcere Zaiming Pharmaceutical Co., Ltd. | Monoclonal antibody for specifically recognizing glypican-3, and application thereof |
| US20240181055A1 (en) | 2021-04-08 | 2024-06-06 | Crage Medical Co., Limited | Cellular immunotherapy use |
| GB202105686D0 (en) * | 2021-04-21 | 2021-06-02 | Imperial College Innovations Ltd | Chimeric antigen receptor (CAR)-T cells |
| GB202105684D0 (en) * | 2021-04-21 | 2021-06-02 | Imperial College Innovations Ltd | Chimeric antigen receptor (CAR)-T cells |
| CN117615786A (zh) * | 2021-05-07 | 2024-02-27 | 森蒂生物科学公司 | 嵌合抗原受体及其使用方法 |
| WO2022261061A1 (en) | 2021-06-08 | 2022-12-15 | Kite Pharma, Inc. | Gpc3 binding molecules |
| CA3237201A1 (en) * | 2021-11-16 | 2023-05-25 | Sotio Biotech Inc. | Treatment of myxoid/round cell liposarcoma patients |
| CN116554348A (zh) * | 2023-04-03 | 2023-08-08 | 上海交通大学医学院附属瑞金医院 | Gpc3-car-t在治疗特发性肺纤维化中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| JP5299942B2 (ja) * | 2005-08-09 | 2013-09-25 | オンコセラピー・サイエンス株式会社 | ＨＬＡ−Ａ２陽性者用ｇｌｙｐｉｃａｎ−３（ＧＰＣ３）由来癌拒絶抗原ペプチド及びこれを含む医薬 |
| US9206257B2 (en) * | 2011-04-19 | 2015-12-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
| EP3692794A1 (en) * | 2011-09-16 | 2020-08-12 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| WO2013070468A1 (en) * | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
| WO2014138314A1 (en) * | 2013-03-05 | 2014-09-12 | Baylor College Of Medicine | Oncolytic virus |
| CN104140974B (zh) * | 2013-05-08 | 2017-09-29 | 科济生物医药（上海）有限公司 | 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞 |
| AU2016304060B2 (en) * | 2015-08-03 | 2022-09-29 | Crage Medical Co., Limited | Antibody against glypican-3 and application thereof |
-
2015
- 2015-09-25 ES ES20196219T patent/ES2851123T1/es active Pending
- 2015-09-25 DE DE20196219.8T patent/DE20196219T1/de active Pending
- 2015-09-25 JP JP2017516350A patent/JP2017529851A/ja active Pending
- 2015-09-25 US US15/513,900 patent/US20170281683A1/en not_active Abandoned
- 2015-09-25 EP EP15845117.9A patent/EP3198010B1/en active Active
- 2015-09-25 ES ES15845117T patent/ES2844700T3/es active Active
- 2015-09-25 WO PCT/US2015/052227 patent/WO2016049459A1/en not_active Ceased
- 2015-09-25 EP EP20196219.8A patent/EP3858991A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mizukoshi et al. | Immune cell therapy for hepatocellular carcinoma | |
| JP2021506243A5 (enExample) | ||
| RU2018113510A (ru) | Химерные рецепторы антигена, нацеленные на psca | |
| RU2017111298A (ru) | Т-КЛЕТКИ С КОСТИМУЛИРУЮЩИМ ХИМЕРНЫМ АНТИГЕННЫМ РЕЦЕПТОРОМ, НАЦЕЛЕННЫЕ НА IL13Rα2 | |
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| JP2019527557A5 (enExample) | ||
| JP2016534717A5 (enExample) | ||
| JP2019528769A5 (enExample) | ||
| HRP20211978T1 (hr) | Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe | |
| JP2019532668A5 (enExample) | ||
| JP2017513478A5 (enExample) | ||
| JP2016502512A5 (enExample) | ||
| RU2017121826A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 | |
| JP2019500894A5 (enExample) | ||
| JP2017522862A5 (enExample) | ||
| MY186846A (en) | Method and compositions for cellular immunotherapy | |
| JP2016508728A5 (enExample) | ||
| RU2018105963A (ru) | Антитело против глипикана-3 и его применение | |
| FI4063397T3 (fi) | Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| JP2017538401A5 (enExample) | ||
| EP4537839A3 (en) | Method and compositions for cellular immunotherapy | |
| JP2015509717A5 (enExample) | ||
| JP2014534207A5 (enExample) | ||
| RU2015117237A (ru) | Химерные антигенные рецепторы м971 | |
| JP2018500337A5 (enExample) |